147 related articles for article (PubMed ID: 28274673)
21. The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.
Cozza G; Venerando A; Sarno S; Pinna LA
Biomed Res Int; 2015; 2015():734127. PubMed ID: 26558278
[TBL] [Abstract][Full Text] [Related]
22. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2.
Syniugin AR; Ostrynska OV; Chekanov MO; Volynets GP; Starosyla SA; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2016; 31(sup4):160-169. PubMed ID: 27590574
[TBL] [Abstract][Full Text] [Related]
24. Acetoxymethyl Ester of Tetrabromobenzimidazole-Peptoid Conjugate for Inhibition of Protein Kinase CK2 in Living Cells.
Viht K; Saaver S; Vahter J; Enkvist E; Lavogina D; Sinijärv H; Raidaru G; Guerra B; Issinger OG; Uri A
Bioconjug Chem; 2015 Dec; 26(12):2324-35. PubMed ID: 26559659
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
[TBL] [Abstract][Full Text] [Related]
26. Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.
Atkinson EL; Iegre J; Brear PD; Zhabina EA; Hyvönen M; Spring DR
Molecules; 2021 Mar; 26(7):. PubMed ID: 33807474
[TBL] [Abstract][Full Text] [Related]
27. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
[TBL] [Abstract][Full Text] [Related]
30. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
31. A Selective Biligand Inhibitor of CK2 Increases Caspase-3 Activity in Cancer Cells and Inhibits Platelet Aggregation.
Rahnel H; Viht K; Lavogina D; Mazina O; Haljasorg T; Enkvist E; Uri A
ChemMedChem; 2017 Oct; 12(20):1723-1736. PubMed ID: 28837260
[TBL] [Abstract][Full Text] [Related]
32. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
[TBL] [Abstract][Full Text] [Related]
33. Kinase CK2 inhibition: an update.
Cozza G; Pinna LA; Moro S
Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
[TBL] [Abstract][Full Text] [Related]
34. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
[TBL] [Abstract][Full Text] [Related]
35. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
36. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
[TBL] [Abstract][Full Text] [Related]
37. Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective.
Grygier P; Pustelny K; Nowak J; Golik P; Popowicz GM; Plettenburg O; Dubin G; Menezes F; Czarna A
J Med Chem; 2023 Mar; 66(6):4009-4024. PubMed ID: 36883902
[TBL] [Abstract][Full Text] [Related]
38. A CE-based assay for human protein kinase CK2 activity measurement and inhibitor screening.
Gratz A; Götz C; Jose J
Electrophoresis; 2010 Jan; 31(4):634-40. PubMed ID: 20162588
[TBL] [Abstract][Full Text] [Related]
39. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.
Cozza G; Zanin S; Sarno S; Costa E; Girardi C; Ribaudo G; Salvi M; Zagotto G; Ruzzene M; Pinna LA
Biochem J; 2015 Nov; 471(3):415-30. PubMed ID: 26349539
[TBL] [Abstract][Full Text] [Related]
40. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
